Author Archives: Joana Fernandes, PhD

Scleroderma Patients May Develop Calcinosis, Study Says

Patients with scleroderma may develop calcinosis, a condition marked by abnormal deposits of calcium salts in the body’s soft tissues, a new study says. The study, “Are there risk factors for scleroderma-related calcinosis?,” was published in the journal Modern Rheumatology. “Calcinosis is commonly found in pressure areas such…

Systemic Sclerosis May Be Linked to Changes in Gut Bacteria, U.S.-Norwegian Study Finds

Systemic sclerosis (SSc) may be associated with changes in gut bacteria, according to a U.S.-Norwegian study which found that SSc patients are more prone to severe gastrointestinal tract (GIT) changes and symptoms. The study, “Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts,” appeared in the…

Insecurity About Care, Isolation and Identity Loss Among SSc Patients’ Concerns, Study Finds

Systemic sclerosis (SSc) patients face significant bodily and social restrictions that undermine their self-image and confidence, and uncertainties about the disease’s cause and prognosis undercut their confidence in their care, according to the a study of patient perceptions. Researchers hope that the data collected for their study — “It’s Not…

Resunab Granted Orphan Drug Status in EU as Potential Therapy for Systemic Sclerosis

The European Commission (EC) has designated Corbus Pharmaceuticals’ product Resunab (JBT-101) an Orphan Drug for the potential treatment of systemic sclerosis (SSc). Orphan Drug status is attributed to therapeutic drugs intended to prevent and treat rare life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people, and…